|
Çí¼½º¾¾¿£¾Ë |
À¯¸Á ¹ÙÀÌ¿À ÄÚ½º´Ú »óÀå¾÷ü CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
04.19 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
±¹³» À¯¸í Á¦¾à»ç ½Å¾à°³¹ß´ã´çÆÀ ÀÓ»ó´ã´ç ä¿ë
¼¿ï ÀüÁö¿ª, ¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
»ó½Ãä¿ë |
12.28 |
|
|
ÅÛÇÁ½ºÅÜÄÚ¸®¾ÆÁÖ½Äȸ»ç |
[ÀϺ»°è ÀÓ»óȸ»ç] Cancer ºÐ¾ß Global PM
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
11.16 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
»óÀ§ CRO»ç-PM ¾÷¹«
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.26 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Therapy Advancement Manager(CRM)/¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
6³â¡è |
ä¿ë½Ã |
11.21 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
¹ÙÀÌ¿ÀÁ¦¾à»ç-ÀÓ»óÅë°è¾÷¹«
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.21 |
|
|
HR ÄÁ¼³Æà |
À¯¸í Á¦¾à»ç ÇØ¿Ü RA Ãʺù
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
03.14 |
|
|
Ä¿¸®¾îÄɾî |
¿Ü±¹°è CRO CRA 1-5³âÂ÷
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
07.24 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
»óÀå´ë±â¾÷-PV ¾÷¹«
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.13 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
»óÀå´ë±â¾÷-ÀÓ»ó¾÷¹«
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.01 |
|
|
ÅÛÇÁ½ºÅÜÄÚ¸®¾ÆÁÖ½Äȸ»ç |
[±Û·Î¹ú ÀÓ»ó±â¾÷] CRM ºÎÀå±Þ
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
10³â¡è |
ä¿ë½Ã |
10.05 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Head of Clinical Development(Clinical Research)/¿Ü±¹°èÁ¦
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
10.23 |
|
|
(ÁÖ)ÄھƼġ |
ÀÓ»ó
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
07.01 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Clinical Research Manager/¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
06.25 |
|
|
(ÁÖ)ž¾Ø½ºÄ«¿ìÆ® |
[À¯¸í Á¦¾àȸ»ç] CRA / ÀǾàÇ° ÀÓ»ó
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
11.09 |
|